˵µ½¸ÎÔ࣬¸÷ÈËÏëµ½µÄÊÇʲô
ÊǹÒÔÚ×ì±ß¡°¸Îµ½ÌìÃ÷¡±µÄ¿ÚÍ·ìø
ÊÇÌå¼ìȱ·¦¸ñÏîÄ¿µÄ³£¿Í¡°Ö¬·¾¸Î¡±
ÕվɸÎÔàΨһÎÞ¶þµÄÔÙÉúÄÜÁ¦?
......
ºÁÎÞÒÉÎÊ£¬¸ÎÔàÕâ¸ö´Ê¸÷È˶¼ÊDz»ÉúÊèµÄ£¬µ«¹ØÓÚ¸ÎÔà×Ô¼º´ó²¿·ÖÈ˾ÍÖªÖ®ÉõÉÙÁË¡£ÏÖʵÉÏ£¬ÎÒ¹úÊÇÒ»¸ö¸Î²¡´ó¹ú£¬Æ½¾ùÿ12СÎÒ˽¼ÒÀï¾ÍÓÐÒ»¸ö¸Î²¡»¼Õߣ¬ÖÚ¶à¸ÎÔ༲²¡µÄ·¢²¡»úÀíºÍÖÎÁÆÒ©ÎïÉÐÓдý̽Ë÷¡£½ñÌìÊÇÌìϸÎÑ×ÈÕ£¬Ð¡±à¾ÍΪ¸÷ÈËÏÈÈݼ¸ÖÖ³£¼ûµÄ¸ÎÔ༲²¡ºÍ³£ÓõĶ¯ÎïÄ£×Ó£¬Öú¸÷ÈËÔÚÑо¿ÖпìÈËÒ»²½¡£
È˵ĸÎÔàλÓÚÉϸ¹²¿£¬ÉÏÓëÓҷΡ¢ÐÄÔàÏàÁÚ£¬ÏÂÓëθ¡¢Ê®¶þÖ¸³¦ÏàÁÚ£¬¸ÎÊÇÈËÌå×î´óµÄÏû»¯ÏÙ£¬Ò²ÊÇÌåÄÚг´úлµÄÖÐÐÄ£¬¾ÝÔ¤¼Æ£¬ÔÚ¸ÎÔàÖб¬·¢µÄ»¯Ñ§·´Ó¦ÓÐ500ÖÖÒÔÉÏ¡£¸ÎÔà¼ç¸º×ÅÓªÑø´úл¡¢½â¶¾ÅŶ¾¡¢Éø͸µ¨Ö¡¢ÃâÒß·ÀÓùµÈ¶àÖÖÖ÷ÒªµÄÐÄÀí¹¦Ð§¡£
¸ÎÔà¼ç¸ºµÄÐÄÀí¹¦Ð§Ö÷ÒªÇÒ·±¶à£¬ÊǽÏÁ¿ÈÝÒס°»ýÀͳɼ²¡±µÄÆ÷¹ÙÖ®Ò»£¬ÎÒ¹úÖÖÖָβ¡µÄ»¼Õß¼ÓÆðÀ´ÓÐ1ÒÚ¶àÈË¡£³£¼ûµÄ¸Î²¡°üÀ¨£ºÖ¬·¾¸Î¡¢¸ÎʵÖÊϸ°ûËðÉË¡¢²¡¶¾ÐÔ¸ÎÑס¢×ÔÉíÃâÒßÐÔ¸ÎÑס¢¸ÎÓ²»¯ºÍ¸Î°©µÈ¡£¶¯ÎïÄ£×Ó¹ØÓÚÑо¿¸ÎÔàÒì³£ºÍ¸ÎÔ༲²¡µÄ²¡ÀíÐÄÀí»úÖÆ£¬ÒÔ¼°È·¶¨ÓÐÓõÄÖÎÁÆÒªÁìºÍɸѡDZÔÚµÄÉúÎï±ê¼ÇÎïÖÁ¹ØÖ÷Òª¡£ÏÂÃ棬С±àΪ¸÷ÈË»®·ÖÏÈÈݸÎÔàÑо¿³£ÓõÄСÊóÄ£×Ó¡£
Ö¬·¾¸Î£¬¸÷È˶¼²»ÉúÊ裬˻¹Ã»¸ö»¼Ö¬·¾¸ÎµÄÅóÙÄØ...
¸ÎÔàÊÇÈËÌåµÄÓªÑøÖÐתվ£¬³ÔÏÂÈ¥µÄʳÎï±»Ïû»¯ÎüÊÕºó»á½øÈë¸ÎÔà¾ÙÐдúл¡£ÈôÊÇÎüÊÕµÄÖ¬·¾Áè¼ÝÁ˸ÎÔàµÄ´¦Öóͷ£ÄÜÁ¦£¬ËüÃǾͻá³Á»ýÔÚ¸ÎÄÚ£¬ÐγÉÖ¬·¾¸Î£¬Ö¬·¾¸ÎÒ»Ñùƽ³£·ÖΪ¾Æ¾«ÐÔÖ¬·¾¸Î£¨Alcohol-related liver disease,ALD£©ºÍ·Ç¾Æ¾«ÐÔÖ¬·¾¸Î(nonalcoholic fatty liver disease£¬NAFLD)Á½´óÀà¡£
¾Æ¾«ÉãÈëºó£¬ÉÙÁ¿»áÁ¬Ã¦ÔÚθÖдúл£¬Ê£ÓàµÄ´ó²¿·Ö¾Æ¾«»á±»Î¸³¦µÀÎüÊÕ£¬Ëæºóͨ¹ý¾²ÂöÔËË͵½¸ÎÔà¡£¸ÎÔàÊǾƾ«´úлµÄÖ÷ÒªÆ÷¹Ù£¬Ëüͨ¹ý¼¸ÖÖø´ÙºÍ·Çø´Ù·´Ó¦»úÖƽ«90%ÒÔÉϾƾ«´úл³ÉÒÒÈ©[1,2]¡£ÒÒÈ©Ö÷ÒªÓÉÒÒ´¼ÍÑÇâø (ADH)¡¢Ï¸°ûÉ«ËØP450 2E1 (CYP2E1) ºÍ¹ýÑõ»¯Çâø±¬·¢¡£ÒÒÈ©Ëæºó±»È©ÍÑÇâø (ALDH) ת»¯³ÉÒÒËᣬ²¢´Ó¸ÎÔàÖÐÊͷųöÀ´£¬±»¼¡ÈâºÍÐÄÔà´úл[2]¡£ÒÒ´¼×Ô¼ººÍËüµÄÑÜÉúÎïÒÒÈ©¿Éʹ¸Îϸ°û±¬·¢Ö¬·¾±äÐÔ¡¢»µËÀ£¬ÉãÈëµÄ¾Æ¾«Áè¼Ý¸ÎÔàµÄÆÊÎöÄÜÁ¦»á¶Ô¸ÎÔàÔì³ÉËðÉË¡£ALDÄ£×ӵĹ¹½¨»ù±¾¶¼ÊÇͨ¹ýСÊóºã¾Ã¹ýÁ¿ÉãÈë¾Æ¾«À´ÔìÄ£µÄ¡£
ALDµÄÖ÷Òª²¡Àíת±ä
½¨Ä£Ð¡ÊóÑ¡Ôñ£º
-
Ʒϵ£ºC57BL/6×î¼Ñ£¬BALB/c ¼°DBAÀÏÊóÔÚÔìÄ£Àú³ÌÖÐÌåÖػήµÍ£¬éæÃüÂʽϸߣ¬²»Ì«ÊÊÓá£C57BL/6ÖУ¬6NÓÖÒª±È6J¸üÒ׸У¨6JµÄÒÒÈ©ÍÑÇâøˮƽ½Ï¸ß£¬¾Æ¾«´úл½Ï6NºÃ£©¡£
-
ÐԱ𣺴ÆÊó¸üÊÊÊÊÓÃÓھƾ«ÐÔÖ¬·¾¸ÎµÄÔìÄ££¬ÓÉÓÚ´ÆÊóθÒÒ´¼ÍÑÇâøˮƽµÍ£¬Í¬Ê±´Æ¼¤ËØÈøÎKufferϸ°û¸üÈÝÒ×Êܵ½ LPS ºÍ´ÙÑ×Ö¢Òò×ÓµÄÓ°Ïì¡£
-
ÖÜÁ䣺8-11ÖÜÁäµÄÀÏÊ󣨳ÉÄêÊ󣩽ÏÁ¿ÊÊÊÊÓÃÓÚÔìÄ££¬ÍíÄê¸Îϸ°ûÄÚÒÒ´¼ÍÑÇâø¡¢ÒÒÈ©ÍÑÇâøºÍCYP2E1»îÐÔ¾ù½µµÍ£¬¸üÒ׳ÉÄ£¡£
½¨Ä£ÒªÁ죺
2.2·Ç¾Æ¾«ÐÔÖ¬·¾¸ÎÄ£×Ó
Åãͬ·ÊÅÖÈËȺµÄ¼¤Ôö£¬·Ç¾Æ¾«ÐԸβ¡£¨NAFLD£©µÄ·¢²¡ÂÊÔÚÒÑÍù20Ä걬·¢ÁËÒ»²¨±¬·¢Ê½µÄÔöÌí¡£NAFLD ÈôÊDz»¿É»ñµÃÓÐÓÃÖÎÁÆ£¬»áÖð½¥Ï£Íûµ½·Ç¾Æ¾«ÐÔÖ¬·¾ÐÔ¸ÎÑ×£¨NASH£©¡¢¸ÎÏËά»¯£¨Fibrosis£©¡£´Ëʱͨ¹ýÆ𾢸ÉÔ¤£¬¸ÎÔàÈÔ¿ÉÄָܻ´Õý³££¬Ò»µ©Ï£Íûµ½¸ÎÓ²»¯£¨Cirrhosis£©£¬½«»áÓÐÔ¼ 1~4% µÄ»¼Õß×îÖÕÏ£ÍûΪ¸Î°©£¨Hepatocellular carcinoma£¬HCC£©¡£ÏÖÔڵļÙ˵ÒÔΪNASHÊǶàÖÖÒòËØÅäÏàÖúÓõÄЧ¹û£¬°üÀ¨ÒÅ´«¡¢·ÊÅÖ¡¢´úл×ÛºÏÖ¢£¨ºÃ±È¸ßѪѹ¡¢¸ßѪÌÇ£©¡¢ÐÄѪ¹Ü¼²²¡¡¢ÌÇÄò²¡µÈ¡£
NAFLD/NASH·¢²¡ÌØÕ÷
ʳԴÐÔ·ÊÅÖºÍÒȵºËضԿ¹ÊÇ×î³£¼ûµÄÈËÀà´úл¼²²¡µÄÓÕÒò£¬ÖÖÖÖÌØÖÆËÇÁϳ£ÓÃÔÚNAFLD/NASHÔìÄ£ÖС£
ALDºÍ NAFLD/NASH ³£ÓÃÄ£×ÓµÄÖ÷ÒªÌØÕ÷
³ýÒûʳÓÕµ¼Í⣬ÎÒÃÇ»¹¿ÉÒÔͨ¹ý»ùÒòÐÞÊεÄÒªÁ죬ÇóýAdh, LdlrµÈÒªº¦»ùÒò£¬×è¶ÏÖ¬·¾´úлÀ´¹¹½¨Ö¬·¾¸ÎÄ£×Ó£¬Ïà¹ØµÄ»ùÒòÐÞÊÎÄ£×ÓÏê¼ûÎÄÄ©±í¸ñ¡£
ÐèҪעÖصÄÊÇ£¬ÀíÏëµÄNAFLD/NASHСÊóÄ£×ÓÓ¦¸ÃÄÜÄ£ÄâÈËÀàNAFLD/NASHµÄ·¢²¡Àú³Ì£¬ÏÖʵÉÏ£¬ÏÖÓеÄÐí¶àÄ£×Ó½öÔÚ×éÖ¯²¡ÀíÉϵÄת±äÓëÁÙ´² NASH ºÜÏàËÆ£¬¿ÉÊǸÎÔàµÄ´úл¡¢¼²²¡µÄ³ÉÒò²¢²»Ïàͬ¡£ÀýÈ磬MCDºÍCDAAÓÕµ¼ËäÈ»¿ÉÒÔÐγÉÓë NASH ÏàËƵIJ¡Àí×éÖ¯Èç·ÊÅÖ¡¢Ñ×Ö¢¡¢ÏËά»¯£¬È»¶ø£¬ÁÙ´² NASH »¼Õß²¢²»»á·ºÆ𵨼îȱ·¦¡£±ðµÄ£¬MCDСÊóÄ£×ӻ᷺ÆðÌåÖØϽµ¶ø²»ÊÇÉý¸ßµÄÌص㣬ÕâÒ»µãÔÚ²¡ÀíÐÄÀíѧÓëÁÙ´²NASHÖ¢×´Ïà·´¡£
¸ÎËðÉË/¸ÎÏËά»¯/¸ÎÓ²»¯Ä£×Ó
¸ÎËðÉËÖ÷ÒªÖ¸¸ÎʵÖÊϸ°ûµÄ¹¦Ð§ËðÉË»ò»µËÀ¡£ÁÙ´²¸ÎËðÉËÖ÷ÒªÓÉÒû¾Æ¡¢Ê³ÎïÖж¾¡¢Ò©ÎﶾÐÔ¡¢²¡¶¾ÐÔ¸ÎÑס¢Ö¬·¾¸Î¡¢¸ÎÓ²»¯¼°µ¨ÖÓÙ»ýÖ¢µÈÒýÆð¡£ÑÏÖصļ±ÐÔ¸ÎËðÉË¿ÉÉú³¤Îª¸ÎË¥½ß£¬Î£¼°ÉúÃü£»ÂýÐÔ¸ÎËðÉËÔò¿ÉÄÜÏò¸ÎÏËά»¯¡¢¸ÎÓ²»¯¡¢¸Î°©µÄÖÕÄ©ÆÚÉú³¤¡£¸ÎÏËά»¯ÏÕЩÅãͬ×ÅËùÓеÄÂýÐԸμ²²¡¡£
ÂýÐԸβ¡µÄÖ÷Òª²¡Àíת±ä
¸ÎËðÉËÔìÄ£Ò»Ñùƽ³£Í¨¹ý¸¹Ç»×¢Éä»òСÊóβ¾²Âö×¢ÉäÌض¨»¯ºÏÎÈ磺CCl4¡¢APAP¡¢ConA¡¢LPS&D-GalNµÈ£©¼´¿É£¬ÔìÄ£ÖÜÆڶ̡£Í¨³£¸ÎËðÉËÄ£×Ó¹¹½¨ÊýСʱºó£¬Ð¡Êó¼´·ºÆð¼±¾çµÄ¸Îϸ°ûéæÃü¡¢¸ÎË¥½ßÄ˼°éæÃü£»¶øµÍ¼ÁÁ¿Öظ´×¢É仯ºÏÎïÔò¿ÉÒÔ»ºÂý»ýÀÛ¸ÎËðÉË£¬µ¼Ö¸ÎÏËά»¯¡¢¸ÎÓ²»¯µÄ±¬·¢¡£
ConA×÷ÓûúÖÆ
-
FahÇóýÄ£×Ó£º»¯Ñ§ÎïÖÊÓÕµ¼¸ÎËðÉËͨ³£ÊÇÇ¿ÁÒÇÒ²»¿ÉÄæµÄ£¬²»¿ÉÄ£ÄâÁÙ´²·Ç»¯Ñ§¸Î¶¾ÐÔÒòËصĸÎËðÉ˵IJ¡Àí״̬ºÍ»úÖÆ£¬Ò²ÎÞ·¨ÊÓ²ì´Ó¸ÎËðÉ˵½¸ÎÓ²»¯ÕâÒ»½¥±äÀú³Ì¡£Í¨¹ýÇóýÒªº¦»ùÒò¹¹½¨ÂýÐÔ¸ÎËðÉËÄ£×Ó¿ÉÒÔսʤÕâ¸öÎÊÌ⣬²¢¿É»ñµÃ´ó×ÚÌØÕ÷¾ùÒ»µÄ¶¯ÎïÄ£×Ó£¬ÈçFah-KOСÊó£¨NM-KO-191202£©£¬ËüÇóýÁËÑÓºúË÷õ£ÒÒõ£ÒÒËáË®½âø(Fumarylacetoacetatehydrolase£¬Fah)¡£Õý³£ÇéÐÎÏ£¬ÀÒ°±Ëá×îÖÕ´úлΪÑÓºúË÷õ£ºÍÒÒõ£ÒÒËá¡£Fah»ùÒòÇóýºó£¬±¬·¢Óж¾µÄÑÓºúË÷õ£ÒÒõ£ÒÒËáÑκÍÂíÀ´õ£ÒÒõ£ÒÒËᣬ²¢±¬·¢Æä´Î¼¶´úл²úÆ·±ûͪ£¬¶Ô¸Î¡¢ÉöÔì³ÉËðÉË£¬ÒýÆð¸ÎÔàËðÉ˺͸ÎÓ²»¯[4]¡£
²¡¶¾ÐÔ¸ÎÑ×Ä£×Ó
²¡¶¾ÐÔ¸ÎÑ×£¨viral hepatitis)ÊÇÓɶàÖÖ²î±ð¸ÎÑײ¡¶¾ÒýÆðµÄÒ»×éÒÔ¸ÎÔàËðº¦ÎªÖ÷µÄѬȾ²¡£¬¿É·ÖΪ¼×¡¢ÒÒ¡¢±û¡¢¶¡¡¢Îì¡¢¸ýÁùÖÖÀàÐÍ¡£ÆäÖУ¬ÒÒÐͲ¡¶¾ÐÔ¸ÎÑ׺ͱûÐͲ¡¶¾ÐÔ¸ÎÑ×£¬¶à¾ÊäѪ»òѪÖÆÆ·ÒÔ¼°Ç×½ü½Ó´¥Èö²¥£¬Ò×ǨÑÓÉú³¤³ÉÂýÐÔÉõÖÁ¸ÎÓ²»¯£¬ÒÑ֤ʵÒÒÐÍ£¨HBV£©ºÍ±ûÐÍ£¨HCV£©¸ÎÑײ¡¶¾Ñ¬È¾Óë¸Î°©ÓÐÒ»¶¨¹Øϵ¡£ÔÚ´ËÖ÷ÒªÏÈÈÝHBVºÍHCVСÊóÄ£×Ó¡£
²¡¶¾ÐÔ¸ÎÑ×·ÖÀà
³£¼ûHBVСÊóÄ£×ÓÔìÄ£ÒªÁìÈçÏ£º
-
lHBV²¡¶¾×¢É䣺½« HBV ÖÊÁ£ DNA Ö±½Ó×¢É䵽СÊóÌåÄÚ£¬ÕâÖÖÔìÄ£ÒªÁì¿ÉÒÔÖÆ×÷²î±ð¶¾ÖêµÄÄ£×Ó£¬ÈõµãÊÇÎȹÌÆڶ̡£
-
AAVתȾ£ºÏÙ²¡¶¾°ü×°HBV»ùÒò×飬ÔÙ¾ÙÐÐ×¢É䣬ÕâÖÖÒªÁìÄÜÐγÉÓëÁÙ´²ÏàËƵÄÃâÒßÄÍÊÜ£¬¿ÉÊÇСÊóÎÞ·¨Öظ´Ñ¬È¾¡£
-
ÈËÒÒ¸Î×éÖ¯ÒÆÖ²£ºÏÖÔÚ×îÍêÕûµÄHBVѬȾģ×Ó£¬¿ÉÔÚСÊóÉÏÄ£ÄâÈËHBVѬȾ£¬ÈõµãÊÇÊÖÊõÖØ´ó£¬Öظ´ÐԲ
-
ת»ùÒòСÊó£ºÍ¨¹ý»ùÒò¹¤³ÌÊÖÒÕ£¬½«HBV»ùÒò×éÇÃÈëСÊó»ùÒò×飬СÊóÄ£×Ó¿ÉÖÕÉú±í´ïHBV£¬ÕâÖÖÄ£×ÓµÄÓŵãÊÇÎȹÌÐÔ¸ßÖظ´ÐԺã¬ÈõµãÊÇÎÞ·¨Ä£ÄâÁÙ´²Ñ¬È¾Àú³Ì£¬ÎÞ·¨¸ù³ýHBV¡£
ÄÏÄ£ÉúÎォc1ÐÍHBV²¡¶¾1.0¿½±´È«³¤DNAתÈëСÊ󣬹¹½¨ÁËЯ´øHBV²¡¶¾µÄת»ùÒòСÊóHBV-Tg£¨»õºÅ£ºNM-TG-00003£©¡£¸Ãת»ùÒòСÊóѪÇåÖÐHBsAg³ÊÑôÐÔ£¬µ«ÎÞHBeAg¡¢anti-HBs¡¢anti-HBe»òantiHBc±í´ï£¬ÎÞHBV DNA¸´ÖÆ¡£ÔÚ¸Ãת»ùÒòСÊóÄ£×ÓµÄѪÇå¡¢¸ÎÔàºÍÉöÔàÖпÉÒÔ¼ì²âµ½Îȹ̱í´ïµÄÈËÒҸβ¡¶¾Íâò¿¹Ô£¬¸ÃСÊóÄ£×ÓΪÑо¿ÈËÀà¡°ÒÒÐ͸ÎÑס±µÄ·¢²¡»úÖÆ¡¢ÖÎÁÆÒªÁìÓëÒ©Îïɸѡ£¬ÌṩÁËÀíÏëµÄ¶¯ÎïÄ£×ÓºÍÐÂÐÍÑо¿ÊֶΣ¬¾ßÓÐÖ÷ÒªµÄÒ½Ò©Ó¦ÓüÛÖµ¡£
ÃâÒß×黯¼ì²âHBsAgÔÚ¸ÎÔà(A)ºÍÉöÔà(B)Öеıí´ï
HCVÖ»ÄÜѬȾÁ鳤À࣬ºã¾ÃÒÔÀ´¶¼Ã»ÓпÉÓõÄС¶¯ÎïÄ£×Ó¡£½« HCV ÔÚÈ˸Îϸ°ûĤÍâò±í´ïµÄÊÜÌå»ùÒòתÈëСÊ󣬿ÉʹСÊóѬȾ HCV£¬ÀýÈçÈËÔ´»¯Ð¡ÊóµÄCD81ºÍOCLN»ùÒò(ÄÏÄ£»õºÅ£ºNM-HU-2000107)£¬¿ÉʹHCV²¡¶¾Õý³£Ñ¬È¾Ð¡Êó¸ÎÔà[10]¡£ÉÐÓÐÑо¿·¢Ã÷£¬Ó¦ÓÃÈËÔ´»¯¸ÎÔàСÊóÒ²¿ÉÒÔ½¨ÉèHCVѬȾСÊóÄ£×Ó[5]¡£
¼øÓÚÁ鳤ÀàºÍÄö³ÝÀàÔÚ²¡¶¾Ò׸ÐÐÔºÍѬȾ»úÖÆÉϵIJî±ð£¬²¡¶¾Ä£×Ó¸ü¶àµÄ½ÓÄÉʳзºï×÷Ϊģʽ¶¯Îï¡£µ«ÔÚÇ°ÆÚµÄÑо¿ÖУ¬×ÛºÏ˼Á¿±¾Ç®µÈ·½ÃæµÄÒòËØ£¬Ò²¿ÉÒÔÑ¡ÔñÃâÒßȱÏÝСÊó×¢ÉäÏìÓ¦²¡¶¾À´ÔìÄ£¡£
¸Î°©Ä£×Ó
¸Î°©µÄ±¬·¢ÊÇÒ»¸ö¶à½×¶ÎÖð½¥Ñݱä¶ñ»¯µÄÀú³Ì£¬´Ó×î³õµÄ¸ÎÑ×µ½¸ÎÓ²»¯£¬ÔÙµ½×îºóµÄ¸Î°©£¬ÊÇÒ»¸ö¶à°ì·¨µÄÉú³¤Àú³Ì¡£¸Î°©Ä£×ӵĹ¹½¨ÒªÁì½Ï¶à£¬¿ÉÒÔÓû¯Ñ§Ö°©¼ÁÓÕµ¼£¬¿ÉÒÔÒÆÖ²¸Î°©Ï¸°û»ò×éÖ¯½¨Ä££¬»¹¿ÉÒÔͨ¹ýÐÞÊÎÒªº¦ÒÖ°©»ùÒò»òÔ°©»ùÒòÔìÄ£¡£
¸ÎÔಡ±äÏ£Íû
Ðí¶à»¯Ñ§Ö°©¼ÁµÖ´ï×ã¹»µÄ¼ÁÁ¿ÊµÊ±¼ä¿ÉÓÕ·¢¶¯ÎïÐγÉÖ×Áö¡£³£Óõĸΰ©ÓÕµ¼¼Á°üÀ¨£º¶þÒÒ»ùÑÇÏõ°·£¨DEN£©¡¢»ÆÇúùËØB1(AFB1)¡¢ËÄÂÈ»¯Ì¼£¨CCl4£©µÈ¡£
ÓÕ·¢ÐԸΰ©Ä£×ÓÓŵ㣺¿ÉÒÔÄ£ÄâÖ×Áö±¬·¢µÄ3¸öÀú³Ì£¬¼´ËðÉË£¬Ó²»¯ºÍÖ×Áö¡£
ÓÕ·¢ÐԸΰ©Ä£×ÓÈõµã£ºÓÕµ¼ÖÜÆÚ³¤£¬ÖÂËÀÂʸߣ¬¸öÌå¼ä¸Î°©±¬·¢µÄʱ¼ä¡¢²¿Î»¼°²¡ÔîÊýµÈ²»¾ùÒ»¡£
5.2 ÒÆÖ²ÐԸΰ©Ä£×Ó
ÒÆÖ²ÐԸΰ©Ð¡ÊóÄ£×ÓÊÇÖ¸½«Ð¡ÊóijÈ˵ĸΰ©×éÖ¯¡¢Ï¸°ûÖê»òÆäËû¶ñÐÔÖ×Áö£¨ÈçÈéÏÙ°©£©ÒÆÖ²µ½Ð¡ÊóÌåÄÚÐγɵĶ¯ÎïÄ£×Ó¡£ÊǸΰ©Ñо¿³£ÓõÄÄ£×ÓÖ®Ò»£¬ÊÊÓÃÓÚ¿¹°©Ò©ÎïÁÙ´²Ç°µÄҩЧÆÀ¼Û¡£
PDXÄ£×Ó
ÏÖÔÚ£¬³£¼ûµÄÒÆÖ²ÐԸΰ©Ä£×ÓÖ÷Òª·ÖΪÁ½ÖÖ£¬Ò»ÖÖÊǽ«ÈËÔ´µÄ¸Î°©Ï¸°ûϵ£¨HepG2, Hep3B, SMMC-7721, HuH7µÈ£©½ÓÖÖµ½ÃâÒßȱÏÝСÊóÌåÄÚ£¬³ÆΪCDXÄ£×Ó£¨cell-line-derived xenograft£©£¬ÁíÒ»ÖÖÊÇδȪԴÓÚ»¼Õߵĸΰ©×éÖ¯¿é½ÓÖÖµ½ÃâÒßȱÏÝСÊóÌåÄÚ£¬³ÆΪPDXÄ£×Ó£¨patient-derived xenograft£©£¬ÄÏÄ£ÉúÎïÒÑÀۼƹ¹½¨Á˽ü°ÙÖָΰ©PDXÄ£×Ó¡£
ʹÓûùÒò¹¤³ÌÊֶι¹½¨µÄ¸Î°©Ð¡Êó²»µ«ÄÜ´Ó¶¯ÎïÕûÌåµÄ×éÖ¯Æ÷¹ÙˮƽÉϾÙÐÐÑо¿£¬²¢ÇÒ»¹¿ÉÒÔÉîÈ뵽ϸ°ûºÍ·Ö×Óˮƽ£¬Îª¸Î°©µÄ·¢²¡»úÖÆ¡¢Ò©ÎïɸѡºÍÁÙ´²Ò½Ñ§Ñо¿ÌṩÀíÏëµÄʵÑ鶯ÎïÄ£×Ó£¬ÄÏÄ£ÉúÎï×ÔÖ÷¹¹½¨Á˶àÖÖÇóý£¬Ìõ¼þÐÔÇóýµÄ¸Î°©Ð¡ÊóÄ£×Ó£¬Ä£×ÓÐÅÏ¢Ïê¼ûÎÄÄ©±í¸ñ¡£
ÄÏÄ£ÉúÎïÉî¸û»ùÒò±à¼ÁìÓò£¬Ìṩȫ·½Î»Ä£Ê½ÉúÎïЧÀÍ£¬°üÀ¨»ùÒòÐÞÊÎÖÆÆ·Ä£×Ó¹©Ó¦¡¢¸öÐÔ»¯Ä£×Ó¶¨ÖÆ¡¢ËÇÑø·±Óý¡¢±íÐÍÆÊÎö¡¢Ò©Ð§ÆÀ¼ÛµÈ£¬Öª×ã²î±ðʵÑéÊÒÐèÇó¡£
²Î¿¼ÎÄÏ×:
1.Ramchandani, V.A.; Bosron, W.F.; Li, T.K. Research advances in ethanol metabolism. Pathol. Biol. (Paris) 2001, 49, 676¨C682.
2.Crabb, D.W.; Matsumoto, M.; Chang, D.; You, M. Overview of the role of alcohol dehydrogenase and aldehyde dehydrogenase and their variants in the genesis of alcohol-related pathology. Proc. Nutr. Soc. 2004, 63, 49¨C63.
3.Nevzorova YA, Boyer-Diaz Z, Cubero FJ, Gracia-Sancho J: Animal Models for Liver Disease - A Practical Approach for Translational Research. J Hepatol 2020.
4.R. Berger, G. P. Smit, S. A. Stoker-de Vries, M. Duran, D. Ketting, and S. K. Wadman, 'Deficiency of Fumarylacetoacetase in a Patient with Hereditary Tyrosinemia', Clin Chim Acta, 114 (1981), 37-44.
5.Humanized Mouse Models for the Study of Hepatitis C and Host Interactions.Cells. 2019 Jun; 8(6): 604, Pages 1-27.
6.Lamas-Paz A, Hao F, Nelson LJ, Vazquez MT, Canals S, Gomez Del Moral M, et al. Alcoholic liver disease: utility of animal models. World J Gastroenterol 2018;24:5063¨C5075.
7.Tsukamoto H, Reidelberger RD, French SW, Largman C. Long-term cannulation model for blood sampling and intragastric infusion in the rat.Am J Physiol 1984;247:R595¨CR599.
8.Corbin KD, Zeisel SH. Choline metabolism provides novel insights into nonalcoholic fatty liver disease and its progression. Curr Opin Gastroenterol 2012;28:159¨C165.
9.Farrell G, Schattenberg JM, Leclercq I, Yeh MM, Goldin R, Teoh N, et al.
Mouse models of nonalcoholic steatohepatitis: toward optimization of their relevance to human nonalcoholic steatohepatitis. Hepatology 2019;69:2241¨C2257.
10.J Virol . 2017 Jan 31;91(4):e01799-16. doi: 10.1128/JVI.01799-16. Print 2017 Feb 15. Mice Expressing Minimally Humanized CD81 and Occludin Genes Support Hepatitis C Virus Uptake In Vivo Qiang Ding, Markus von Schaewen, Gabriela Hrebikova, Brigitte Heller, Lisa Sandmann, Mario Plaas, Alexander Ploss.